The Ervebo vaccine is made by Merck and is being used in a “compassionate use” capacity in the eastern Democratic Republic of Congo, site of the second-largest, second-deadliest Ebola outbreak on record, ABC News reported.
The WHO’s pre-qualification of the vaccine means that it meets the agency’s quality, safety and efficacy standards.
The vaccine’s approval is “a historic step,” according to WHO Director-General Tedros Adhanom Ghebreyesus, ABC News reported.
“Five years ago, we had no vaccine and no therapeutics for Ebola,” he said in a statement. “With a pre-qualified vaccine and experimental therapeutics, Ebola is now preventable and treatable.”
Copyright © 2019 HealthDay. All rights reserved.
Article source: http://www.medicinenet.com/script/main/art.asp?articlekey=225941